Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SMC recommends Napp's bendamustine in CLL, Genzyme's Renvela and ... er, well ... that's all

This article was originally published in Scrip

Executive Summary

Of the latest batch of verdicts to come out of Scotland's health technology assessment body, the Scottish Medicines Consortium, only Napp Pharmaceuticals' bendamustine (Levact) received a positive decision for use in chronic lymphocytic leukaemia. The Consortium was convinced that bendamustine was cost-effective for stage B and C CLL in patients who had not responded to the cheaper combination chemotherapies including fludarabine, even though it thought Napp had significantly underestimated the cost of the Quality Adjusted Life Year gain for the drug.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC012570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel